Immutep 대차 대조표 상태

재무 상태 기준 확인 6/6

Immutep 의 총 주주 지분은 A$189.5M 이고 총 부채는 A$960.8K, 이는 부채 대 자기자본 비율을 0.5% 로 가져옵니다. 총자산과 총부채는 각각 A$201.6M 및 A$12.1M 입니다.

주요 정보

0.5%

부채 비율

AU$960.76k

부채

이자 보상 비율	n/a
현금	AU$181.88m
주식	AU$189.52m
총 부채	AU$12.06m
총 자산	AU$201.58m

최근 재무 상태 업데이트

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

재무 상태 분석

단기부채: IMM 의 단기 자산 ( A$191.4M )이 단기 부채( A$10.5M ).

장기 부채: IMM 의 단기 자산( A$191.4M )이 장기 부채( A$1.6M ).

부채 대 자본 내역 및 분석

부채 수준: IMM 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: IMM 의 부채 대 자기자본 비율은 지난 5년간 31.3% 에서 0.5% 로 감소했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: IMM 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: IMM 25.6 2.3 25.6 % 매년.

Immutep 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Consensus revenue estimates increase by 64%

Consensus revenue estimates increase by 16%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

No longer forecast to breakeven

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Price target increased by 8.1% to AU$0.97

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Price target decreased by 29% to AU$0.90

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 54%

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Consensus EPS estimates upgraded to AU$0.024 loss

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Consensus EPS estimates fall by 58%

Immutep Limited, Annual General Meeting, Oct 24, 2023

Consensus revenue estimates decrease by 77%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to AU$0.052 loss

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 23%

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 19%

Price target increased by 15% to AU$1.33

No longer forecast to breakeven

Consensus revenue estimates increase by 20%

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Consensus forecasts updated

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Consensus forecasts updated

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Consensus forecasts updated

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

No longer forecast to breakeven

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC